TBPH Q3 2017 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$700M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-77.6% YoY

Gross Profit

$3M77.0% margin

Operating Income

-$57M-1333.3% margin

Net Income

-$67M-1564.4% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+21.8%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$63M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$486M

Total Liabilities

$302M

Stockholders' Equity

$184M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$19M	-77.6%
Gross Profit	$3M	$19M	-82.4%
Operating Income	-$57M	-$33M	-70.2%
Net Income	-$67M	-$34M	-96.9%